Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study

Journal of the Egyptian National Cancer Institute

Volumn 23, Issue 1, 2011, Pages 17-24

  Abdelhamid, Thoraya ^a   Samra, Mohamed ^a   Ramadan, Hanan ^a   Mehessin, Marowa ^b   Mokhtar, Nadia ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Aa IPI; CHOP regimen; DLBCL; IPI; Prognostic and predictive factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGE ADJUSTED INTERNATIONAL PROGNOSTIC INDEX; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84864360370     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2011.07.003     Document Type: Article

References (22)

1. No authors listed. A clinical evaluation of the international lymphoma study group classification of non Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997;89:3909-18.
2. Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S., Küppers R., Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphoma. Nature 2001, 412:341-346.
3. Mokhtar N. Cancer pathology registry (1998-2000). National Cancer Institute. Cairo University.
4. No authors listed. A predictive model for aggressive non Hodgkin's lymphoma. The international non Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329:987-94.
5. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin lymphoma. N Engl J Med 1993, 328:1002-1006.
6. Blayney D.W., LeBlane M.L., Grogan T., Gaynor E.R., Chapman R.A., Spiridonidis C.H., et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate and high grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG9349). J Clin Oncol 2003, 21:2466-2473.
7. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
8. Chu E., DeVita V.T. Principle of cancer management chemotherapy. Cancer: principles and practice of oncology 2001, 1957. Lippincott Williams and Wilkins, Philadelphia, Baltimore, New York, London. 6th ed. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
9. Alizadeh A.A., Elsen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
10. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised international prognostic index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109(5):1857-1861.
11. Mckelvey E.M., Gottlieb J.A., Wilson H., Haut A., Talley R.W., Stephens R., et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484-1493.
12. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M.M., Grogan T.M., Mize E.M., et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients in intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol 1994, 5(Suppl. 2):91-95.
13. Shipp M.A., Abeloff M.D., Antman K.H., Carroll G., Hagenbeek A., Loeffler M., et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999, 17:423-429.
14. Coffier B., Lepage E., Brier J., Herbrecht R., Tilly H., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002, 346(4):235-242.
15. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP vs. CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
16. Lee K.W., Kim D.Y., Yun T., Kim D.W., Kim T.Y., Yoon S.S., et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcome between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003, 98(12):2651-2656.
17. Yang S., Yu Y., Jun-Min L., Jian-Qing M., Qiu-Sheng C., Yu C., et al. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B cell lymphoma in an era of R-CHOP in Chinese population. Ann Hematol 2009, 88(9):863-869.
18. Colomo L., López-Guillermo A., Perales M., Rives M., Martinez A., Bosch F., et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003, 101(1):76-84.
19. Sehen L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109(5):1857-1861.
20. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Respect of average related dose intensity correlate with survival in diffuse large B-cell lymphoma patients treated by CHOP. National retrospective study (1995-2000). Poster presented at the 46th Annual meeting of the American Society of Hematology; 2004, San Diego, Calif. Abstract 3316.
21. Hirakawa T., Yamaguchi H., Yokose N., Gomi S., Inokuchi K., Dan N., et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 2010, 89:897-904.
22. Terada Y., Nakamae H., Aimoto R., Kanashima H., Sakamoto E., Aimoto M., et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 2009, 28:116.